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The Italian Consensus Conference on clinical management of atopic dermatitis in children reflects the best and
most recent scientific evidence, with the aim to provide specialists with a useful tool for managing this common,
but complex clinical condition. Thanks to the contribution of experts in the field and members of the Italian Society
of Pediatric Allergology and Immunology (SIAIP) and the Italian Society of Pediatric Dermatology (SIDerP), this
Consensus statement integrates the basic principles of the most recent guidelines for the management of atopic
dermatitis to facilitate a practical approach to the disease. The therapeutical approach should be adapted to the
clinical severity and requires a tailored strategy to ensure good compliance by children and their parents. In this
Consensus, levels and models of intervention are also enriched by the Italian experience to facilitate a practical
approach to the disease.
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Utilizing the best and most recent scientific evidence,
the aim of this Consensus is to provide specialists with a
useful tool for managing this apparently simple, but in
reality complex, clinical condition. To this purpose, the
Consensus has been divided into three main sections
(Topical therapies, Systemic therapies, Non-pharmacological
interventions), and the key aspects of each of these have
been considered. Summary boxes in the text highlight the
fundamental measures to be implemented, with details de-
lineated within each section. The important topic of thera-
peutic education is discussed within section 3. The
selection of therapies for individuals with atopic dermatitis
should be influenced by the clinical appearance of lesions,
and the application of topical products requires a tailored
approach to ensure good compliance by children and their* Correspondence: giampaolo.ricci@unibo.it
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tion are based on the Italian experience, but also informed
by models of care in other countries such as Germany,
where therapeutic education for atopic dermatitis is ap-
proved and reimbursed by the National Health System.
The basic principles of the “International Dermatology
and Allergy Guidelines for Atopic Dermatitis Management”
are integrated into this consensus statement to facilitate a
practical approach to the disease [1].
Topical therapies
Skin care: moisturizers and cleansers
Maintaining skin barrier function is an important thera-
peutic goal and a priority of treatment algorithms from
the most prominent scientific societies worldwide [2–6].
However, validated therapeutic regimens for acute and
chronic phases of atopic dermatitis (AD) in children are
still lacking. AD is known to be a chronic disease, which
in most cases is mild or moderate but can be severe
enough in some patients to require systemic therapy.
The clinical picture is typically characterized by alternate
periods of remissions and exacerbations, while it candistributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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properly conducted topical therapeutic regimen is usu-
ally sufficient to obtain good control of the AD.
Hygiene: detergents
Cleansing is recommended for patients with AD as part
of maintenance therapy (strength of recommendation C -
level of evidence II, according to the recent US guidelines)
[4]; however, there is no unanimity in recommendations
about the frequency and duration of washes [4, 7]. In fact,
the guidelines on the one hand suggest frequent washing
to remove crusts and allergens (eg. dust mites) and to re-
duce colonization by S. aureus, while on the other warn
against damaging the skin barrier with cleaning that is too
aggressive [3–6]. Some authors suggest the use of daily
baths with lukewarm water of short duration (eg. 5 min),
followed by gentle drying with smooth cloths and appli-
cation of emollients while the skin is still damp [8].
When inflamed lesions are poorly responsive to anti-
inflammatory treatment, the so-called soak and smear
method has been recommended because it can produce
a higher absorption of topical steroids; this method con-
sists of washing for 20 min followed by the application
of topical anti-inflammatory steroid, without first drying
the affected areas [9, 10]. Although there are currently
few clinical studies, the use of non-soap cleansers and
synthetic detergents (the so-called syndets) are recom-
mended; these products have a slightly acidic pH (pref-
erably about 5.5–6), should be free or relatively free of
preservatives and perfumes, and have liquid formula-
tions to facilitate rinsing [4, 11, 12]. Recently, the rec-
ommendation of the use of washes with diluted sodium
hypochlorite (NaClO) has been reaffirmed; dilute
NaClO was studied in 2007 and shown to be effective in
countering the proliferation of S. aureus, a known cause
of AD flares [3, 4, 8, 13, 14]. This treatment is recom-
mended in combination with nasal mupirocin in pa-
tients with moderate-severe AD and clinical signs of
bacterial superinfection [4] (see Chapter 1.3 “Topical
antimicrobials”). To date, the addition of oils or other
antiseptic products to detergents is supported by a few
studies, but with conflicting results and without ran-
domized controlled clinical trials (RCTs) they cannot be
recommended for clinical practice [4, 15, 16]. Oily
cleansers containing mineral oils are preferred toTable 1 Characteristics of the main emollients
Product
1st-generation emollients Vaseline, paraffin oil, fatty alcohols, hydrophilic
(collagen, ac. hyaluronic acid, chitosan, polysac
2nd-generation emollients Glycerol, sorbitol, substitutes NMF (Natural Moi
of pyrrolidone carboxylic acid, urea (5–10 %), la
3rd-generation emollients Physiological lipids: ceramides, cholesterol, polyminimize allergenicity, but the short duration of contact
with the detergent normally decreases its ability to in-
duce sensitization and trigger contact eczema [16].
Moisturizers - emollients
The use of topical moisturizers and emollients is an es-
sential element of the treatment and prevention of xero-
sis recommended by published guidelines (strength of
recommendation A, level of evidence I) [2–5]. Random-
ized controlled clinical trials conducted on the use of
topical moisturizers have proven their effectiveness in
preventing AD relapses with a consequent reduction in
the use of topical steroids [17–25]. Emollient products
may be classified according to their composition
(Table 1), with different proportions of emollient agents.
These agents moisturize the skin and reduce transepider-
mal water loss through occlusive properties (eg. Vaseline),
or by attracting and holding onto water through humec-
tant properties (eg. collagen, hyaluronic acid and other
molecules with high molecular weight) [4]. Preparations
with a hydrophilic base (for example preparations contain-
ing urea in percentages varying from 5 to 10 %) are avail-
able and can be used, depending on the type and site of
the lesions to be treated (especially in dry and very dry
areas) and the age of the child and the age of the child (i.e.
emollients containing urea above 3 years of age) [3]. Some
of the more recently marketed emollients contain various
molecules such as glycerol, analogues of the Natural
Moisturizing Factor (NMF), and lactic acid and may act
by improving hydration and the integrity of the skin bar-
rier. In recent years other emollients that contain physio-
logic lipids (ceramides, polyunsaturated fatty acids and
cholesterol, which promote epidermal differentiation and
correct the deficiency of lipids among corneocytes) have
been developed; when it’s possible the use of third gener-
ation emollients is preferable. It is not possible to give de-
finitive guidance concerning the frequency of application
and the amount of product to use, because there are not
sufficient clinical studies to address these issues [4, 26].
However, recent guidelines suggest modulating the fre-
quency of application according to xerosis, climatic condi-
tions and patient sports/activities (eg. swimming) [24]. It
is recommended to use a proper amount of product quan-
tities of (150–200 g/week are recommended for children,
and up to 500 g/week is recommended for adults) [3, 24].Action
polymers
charides gelling)
Hygroscopic and occlusive
sturizing Factor) derivatives
ctic acid, ammonium lactate
Restoring hydration and barrier function
unsaturated fatty acids Barrier repair therapy
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more or less fluids, creams or milks. Products with a
higher fat content may be preferred during the winter sea-
son [3]. Finally, there are medicated cosmetics and med-
ical devices which are also proposed as therapeutic aids
(prescription emollient devices; PEDS). They contain a
base to which natural anti-inflammatory agents such asTable 2 Main studies conducted on the use of emollients in pediatr
MC. et al. 2012 [6])
Population Treatment Fre
du
app
Infants (age <12 months)
with moderate to severe
AD (n = 173).
Grimalt et al. 2007 [21]
Emollient containing oat extract
(Exomega, Laboratories Pierre
Fabre, France)
Tw
6 w
Infants and young children
(aged 2 months-6 years)
with mild to moderate AD (n = 25)
Nebus et al. 2008 [30]
Occlusive cream containing
colloidal oatmeal and detergent
with colloidal oatmeal and
glycerin (Aveeno, Johnson &
Johnson Consumer Companies,
Inc., Skillman, USA)
Cre
4 w
Cle
wa
Children (aged 3 months-16 years)
with mild to moderate AD (n = 65)
Kircik et al. 2011 [31]
Emulsion containing ceramides
(EpiCeram)
Tw
3 w
Children with AD (aged 6 months-
12 years) (n = 76)
Giordano-Labadie et al. J 2006 [32]
Moisturizing milk (Exomega)
compared to control
Tw
2 m
Children (aged 6 months-12 years)
with mild to moderate AD (n = 142)
Breternitz et al. 2008 [17]
Glycyrrhetinic acid based cream
(Atopiclair) compared to vehicle
Thr
43
Children and adolescents
(aged 6 months-18 years)
with mild to moderate AD (n = 121)
Sugarman et al. 2009 [29]
Emulsion-containing ceramides
(EpiCeram) compared to topical
fluticasone (Cutivate,
Pharmaderm, Melville, NY, USA)
Tw
Children (aged 1.5–12 years)
with resistant treatments/
recalcitrant AD (n = 24)
Chamlin et al. 2002 [27]
Emulsion containing ceramides
(Triceram, Osmotics Corp., Denver,
CO, USA) instead of the previous
moisturizer, continuing topical
tacrolimus or topical
corticosteroids
Tw
12
day
Children and adolescents (aged 2–
17 years) with mild to moderate
AD (n = 39)
Miller et al. 2011 [33]
Glycyrrhetinic acid based cream
(Atopiclair) vs. ceramide- based
emulsion (EpiCeram) vs. petrolatum-
based ointment (Aquaphor Healing
Ointment, Beiersdorf Inc., Wilton, CT,
USA)
Thr
3 w
Children and adults
(aged 2–70 years) with mild
to moderate AD (Study 1,
n = 66; Study 2, n = 127)
Simpson et al. 2011 [34]
Cetaphil Restoraderm
moisturizing (Galderma
Laboratories, Fort Worth, TX, USA)
Stu
4 w
twi
in
corbisabolol (obtained from chamomile), glycyrrhetinic acid
(obtained from liquorice), and/or essential omega 6 fatty
acids are typically added. However, controlled studies
comparing the effectiveness of these products are still
limited and they have not demonstrated greater efficacy
than traditional agents [6, 14, 21, 27–34] (Table 2). Re-
cently, some articles have considered the use of specificic patients with atopic dermatitis (modified from Mack Correa
quency and
ration of
lication
Efficacy Safety
ice/day for
eeks
Significant reduction in the use
of high potency topical CS and
improvement of SCORAD and QoL
Two severe
reactions.
Good
tolerability in
94 % of
patients.
am: twice/day for
eeks
Significant improvement of IGA,
dryness and itching at 2 and
4 weeks; QoL significantly
improved at 4 weeks
Well
tolerated; no
severe
reactions
related to
treatment
ansing: every
sh
ice/day for
eeks
Improvement of IGA, patient
satisfaction and QoL
No severe
reactions to
the
treatment
ice/day for
onths
Significant improvement of
dryness, itching and QoL
Satisfactory
or excellent
level of
tolerance in
97 % of
patients
ee times/day for
days
Significant improvement of IGA,
reduced use of topical
corticosteroids
No severe
reactions
related to
the
treatment
ice/day for 28 days Significant improvement in SCORAD
index. Comparable effectiveness
between the two treatments
No severe
reactions
related to
treatment
ice/day for
weeks, then once/
for 9 weeks
Significant improvement of SCORAD
in 92 % of patients within 3 weeks,
in 100 % within 21 weeks; decrease
of trans-epidermal water loss; hydra-
tion and integrity of the stratum cor-
neum improved
No severe
reactions
related to
treatment
ee times/day for
eeks
Improvement in the 3 treatment arms
with no difference; Ointment-based
petrolatum showed the best
improvement measured through
clinical evaluation
No severe
reactions
related to
treatment
dy 1: twice/day for
eeks; Study 2:
ce/day for 4 weeks
addition to topical
ticosteroid.
Study 1: significant decrease in
pruritus and improvement of
hydration and QoL. Study 2: only
compared to steroid: significant
improvement of hydration, decrease
in EASI score and more rapid action
No severe
reactions
related to
treatment
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ally susceptible infants; a trial conducted on 124 infants
at high risk for AD has shown that the application of an
emollient on the skin surface reduces by 50 % the inci-
dence of the disease evaluated at 6 months of life [35]
and similar results were observed by other authors in
preterm infants [36–38].
Summary box
Cleansing
 Bathe for short amounts of time in warm water with
gentle cleansers relatively free or free of
preservatives and perfumes.
 Dry skin gently with smooth cloths
 In case of bacterial superinfection, use wash
containing dilute sodium hypochlorite.
Hydration
 Emollients are the backbone of AD therapy.
 The most appropriate formulation should be chosen
and applied at least daily to the entire surface of the
skin in sufficient quantity to minimize xerosis,
which may be affected by weather conditions and
sports/activities.
 The constant use of emollients, even during
remission, prevents flares and decreases the use of
topical steroids.
Topical corticosteroids
Topical corticosteroids (TCS) are still considered the
mainstay of pharmacological treatment and the first
choice drugs for AD therapy [4]. The use of TCS for ec-
zema goes back about 60 years, and their effectiveness
has been demonstrated in more than one hundred RCTs
[39]. They are anti-inflammatory medications that can
be applied to damaged skin to treat eczema in any stage
of inflammation and to reduce itching [39–41]. They act
on a multitude of cells of the immune system, such as TTable 3 Topical corticosteroids are divided into 4 groups according
Group I Group II
Low power Moderately powerful
• Hydrocortisone
• Hydrocortisone Acetate
• Aclometasone dipropionate
• Clobetasol butyrate
• Dexamethasone sodium phosphate
• Dexamethasone valerate
• Desonide
• Fluocortinbutilestere
• Hydrocortisone butyratelymphocytes, monocytes, macrophages and dendritic
cells. It is hypothesized that TCS may act by interfering
with the mechanisms of antigen processing, by binding
to specific cell receptors, and by suppressing the release
of pro-inflammatory cytokines [4, 41]. Taking into ac-
count these mechanisms of action, it is proposed that
the antipruritic effect of TCS is best appreciated when
the itching is secondary to inflammation [41]. The opti-
mal dose of TCS can be standardized in finger tip units,
a quantity of product that can be squeezed from a tube
along the distal phalanx of the index finger of an adult
hand; this amount containing approximately 0.5 g is the
proper amount to be applied to a surface as large as two
palms of the hands of an adult [42]. TCS should be
applied after adequate cleansing of the area to be
treated [43].
In order to achieve long-term therapeutic effects,
important consideration should be give to:
A)Choice of TCS, which depends on the strength and
vehicle of the preparation. TCSs are categorized
into four groups according to strength; with group
I being the weakest and group IV being the
strongest (Table 3). In addition, the vehicle affects
the strength of TCS, with creams generally less
strong than ointments containing same active drug
component. The choice of the formulation
depends on the surface area and location of
eczema [44] (Table 4).
However, we must always keep in mind some
considerations:
 TCS are indicated for the treatment of eczema and
not of xerosis and/or lichenification; these
manifestations should be treated with moisturizers
after resolution of the acute phase;to their power (from Patrizi and Gurioli [270])
Group III Group IV
Powerful High power
• Beclomethasone dipropionate
• Betamethasone benzoate, dipropionate
and budesonide valerate
• Budesonide
• Desossimetazone
• Diflucortolone valerate
• Diflucortolone valerianate
• Fluocinolone acetonide
• Fluocinonide
• Fluocortolone
• Fluocortolone caproate
• Fluticasone propionate
• Methylprednisolone aceponate
• Mometasone furoate
• Prednicarbate
• Halcinonide
• Clobetasol propionate
Table 4 Choice of CTS formulation according to the phase and
location of AD
Phase of eczema Formulation of CTS
Dry erythema Cream/Milk
Erythema with lichenification Ointment
Erythema with exudation Lotion/Cream
Hairy areas Lotion/foam/gel
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 Topical agents should be applied in a thin layer until
absorbed, as excess material can cause irritation;
 The selected formulation should be cosmetically
acceptable to the patient in order to encourage good
compliance.
B) Frequency of application and duration of treatment.
The use of TCS is most commonly once or twice a
day, preferentially in the evening, as there is no
evidence that more frequent application produces
better results; indeed, there are no convincing data
to suggest that daily administration is less effective
than twice daily [45, 46]. There is no consensus in
the literature regarding the duration of therapy.
Medium-high potency TCS are generally preferred in
the acute phases because they can lead to a significant
benefit in the short term [47]. These therapies should
be continued over each single lesion until its resolution
of eczema is achieved, then can be reduced and
gradually stopped or changed to a less strong TCS
(according to the concept of minimum effective
dose) [4]. Greater attention must be paid to thinner
skin, eg. eyelids or neck, because there is a greater
risk of absorption and local atrophy. In these locations,
especially if frequent applications of TCS are needed,
preparations with reduced systemic absorption and
lower risk of skin atrophy are preferred. Examples
include newer generation TCS (eg. fluticasone
propionate, methylprednisolone aceponate,
mometasone furoate, desonide) or immunomodulators
such as topical calcineurin inhibitors (see Chapter 1.4
“Topical immunomodulators”).
Once the healing is achieved (regression of eczema
and improvement or resolution of itching), the goal of
therapy should be to extend the relapse-free time as long
as possible. For this purpose, emollients can be effective,
but patients or family members should be educated to
reapply topical steroid immediately in case of relapse.
The maximum monthly amount of medium or high po-
tency TCS to be used to avoid local and/or systemic side
effects is equal to 15 g in infants, 30 g in children, and60–90 g in adults [3, 42]. In the last few years, another
type of approach to maintanance care is being promoted,
the so-called “proactive” approach. This new treatment
strategy is particularly useful for optimizing clinical con-
trol in patients with frequent AD flare-ups. The “pro-
active” therapy should be started after eczema heals. It
consists of applying TCS intermittently once or twice a
week in the areas most prone to relapse, even when no
inflammatory lesions are visible. This strategy reduces
the number of relapses and lengthens the interval free
from symptoms more effectively than the use of emol-
lients alone [42, 48]. The rationale of proactive therapy
is to obtain control of subclinical disease by using min-
imal amounts of TCS [46, 49]. In patients with exudative
lesions and/or erosions, the application of TCS and even
emollients can cause burning and may be poorly toler-
ated, especially in young children. In these cases the use
of compresses may reduce exudation and promote re-
epithelialization of lesions. The incidence of side effects
from new generation TCS is very low [4]. However, the
long-term use of TCS, especially if high potency, may
cause local side effects. In rare cases, systemic effects
may occur, more frequently in children due to the high
ratio of total body surface area to body mass, which is
about 2.5 to 3 times higher than for adults [50].
Normally, just 1 % of the TCS applied supplies all of
its therapeutic action; the remaining 99 % is removed
from the skin surface by rubbing, washing and exfoli-
ation [50]. Despite this, prolonged exposure to high
potency or older generation TCS, as may occur with
occlusion, may lead to significant systemic absorption
and suppression of the hypothalamic-pituitary-adrenal
axis, especially if there is concurrent use of cortico-
steroids for other conditions (rhinitis, asthma) [51].
Main side effects of TCS are striae rubrae, skin atro-
phy, telangiectasia, skin burning, erythema and acnei-
form eruptions [52].
Among the side effects that are most feared is local
skin atrophy [53]. The mechanism through which skin
atrophy can be induced includes the inhibition of fibro-
blast proliferation, as well as reduced synthesis of colla-
gen. Recent data are fairly reassuring about the risks of
skin atrophy; in a study exploring skin thickness before
and after prolonged use of moderate quantities of
medium and high power topical steroids (not exceeding
the above recommendations), atrophy was not observed
in the treated areas [52]. Other studies have shown that
skin atrophy due to TCS is a reversible phenomenon,
and that healing may occur after a few weeks of TCS
therapy discontinuation [54]. The possibility of contact
dermatitis should be taken into consideration, especially
when eczema worsens or does not respond to properly
administered TCS therapy [4]; in these cases, the
performance of patch tests for diagnostic purposes is
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superinfection with staphylococcus [55]. Even more rare
is the observation of systemic side effects on growth,
hyperglycemia, hypertension and glaucoma, reported in
very old studies during systemic therapy [56] and even
less frequently described for local therapies [50].
A systematic review of the literature on the side ef-
fects of TCS concluded that the safety profile of new
TCS is good when used as directed [57]. However,
corticophobia is commonly observed among families
and even doctors [58, 59]. This is a condition to be
avoided, as insufficient and inadequate applications of
TCS limit ability to control dermatitis and can worsen
therapeutic compliance [52, 60]. Especially in severe
forms of AD, it is therefore important to implement a
multidisciplinary approach, in which therapeutic edu-
cation has an important role. TCSs constitute the first
choice therapy for eczema, and in the majority of
cases, they are able to maintain good control of the
dermatitis, with benefits that greatly exceed the un-
common iatrogenic risks [50].
Summary box
 TCSs represent the cornerstone therapy for eczema,
especially for the moderate/severe forms: they
should be applied on damaged, erythematous and/or
exudative skin.
 Their effectiveness is related to their potency
(Table 3), the vehicle of the preparation (Table 4),
and the application modality.
 TCS potency and vehicle (ointments, creams,
lotions, milks or foams) should be chosen depending
on the age of the patient, sites and types of eczema.
 Once daily application in the evening and continued
use until complete resolution of lesions is a
preferred method
 In cases of relapsing AD, “proactive” therapy should
be encouraged, with the application of TCS twice a
week (in the evening) on areas of frequent relapses.
 The safe monthly dose of medium to high potency
TCSs is 15 g in infants, 30 g in children, 60–90 g in
adolescents-adults.
 Newer generation TCS have a good safety profile,
especially if used properly.
Topical antimicrobials
Skin infections in patients suffering from AD are most
frequently caused by S. aureus, S. pyogenes and H. sim-
plex virus (HSV). In patients with AD, the prevalence of
colonization of the skin and/or nose by S. aureus varies
from 60 to 100 %, while in control subjects without AD
it varies from 5 to 30 %. A correlation between bacterial
colonization and severity of eczema has also been re-
ported in the literature [61]. Some toxins produced by S.aureus act as superantigens: they are able to produce a
massive activation of T cells and contribute to exacerba-
tion of skin lesions. The toxins also seem to induce the
production of specific IgE, the activation of basophils,
and consequently, the inflammatory cascade [62].
Topical antibiotic therapy is indicated for treatment of
monofocal bacterial infections or confined impetigo, but
not for simple colonization. Most topical antibiotics are
available in two formulations: cream and ointment.
Cream is preferable for treating exudative lesions, while
ointment is preferable for dry lesions with a desquama-
tive component (microbial eczema with lichenification).
Fusidic acid and mupirocin are the most appropriate an-
tibiotics; ideally they should be applied twice a day with
bandage or 3 times a day without bandage for 7–10 days
[63–65]. Since mupirocin-resistant staphylococci strains
have been isolated, treatment should not be prolonged
over 10 days [62]. Mupirocin should not be used in chil-
dren younger than 1 year, because of a lack of studies on
this age group. Since 2007, Retapamulin has been ap-
proved in the US for pediatric patients above 9 months
old for the treatment of impetigo with S. pyogenes and
methicillin-resistant S. aureus [66]. The recommended
therapeutic regimen is 2 applications a day for 5 days
[67]. The effectiveness of 5 days of Retapamulin oint-
ment therapy is comparable to that of fusidic acid used
longer; however it should be reserved for strains re-
sistant to conventional treatments. The recurrence of
infections in patients with AD is frequently associated
with nasal colonization by S. aureus; when nasal swab
is positive for S. aureas, nasal decolonization with
mupirocin (after execution of antibiogram) has been
proven effective, with 2 applications a day in both
nostrils for 5 days per month, for a variable period of
3–18 months [63]. The most frequently reported side
effects after the application of topical antibiotics in-
clude irritation, itching, and contact dermatitis. Epi-
sodes of contact dermatitis are generally attributed to
excipients or preservatives contained in the medicine
(i.e. lanolin, cetyl alcohol, stearyl alcohol) [68]. The
existence of multiple strains of S. aureus resistant to
the most common antibiotics represents a major chal-
lenge in the treatment of staphylococcal infections.
Over the past 10 years, there has been a significant
increase in impetigo caused by S. aureus resistant to
treatment with fusidic acid, probably due to its wide-
spread and often inappropriate use in chronic derma-
toses [68, 69]. The use of topical antibiotics in the
treatment of patients with AD and impetigo permits
healing of the infection with less absorption and very
low risk of systemic side effects. The duration of
treatment should be restricted to the treatment of im-
petigo to prevent any risk of sensitization and/or the
development of drug resistance.
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 Topical antibiotics fusidic acid and mupirocin are
indicated for the treatment of a monofocal bacterial
superinfection (2–3 applications/day for 7-10 days).
 When S. aureus infection recurs, nasal
colonization should be suspected and nasal
swabbing should be performed. If positive, treat
with nasal mupirocin for 3-18 months (2 applications/
day for 5 days per month).
 For strains resistant to conventional treatments,
retapamulin ointment is indicated as second-line
treatment.
Topical immunomodulators
Tacrolimus (Protopic®) and pimecrolimus (Elidel®) be-
long to the topical immunomodulators (TIMs) class that
acts by inhibiting the activity of calcineurin; they were
approved in 2000 and in 2001, respectively, for the treat-
ment of AD in adults and children older than 2 years of
age [70, 71]. Tacrolimus is produced by the bacterium
Streptomyces tsukubaensis, while pimecrolimus is a
chemical derivative of ascomycin, produced by Strepto-
myces hygrospicus [72]. TIMs inhibit the activation of T
cells through a highly selective mechanism of action that
provides good control of the disease and a low risk of
side effects. They are especially useful when long-term
therapy is needed or when TCS would cause undesirable
side effects (eg. on sensitive areas like the eyelids) [73].
Tacrolimus also acts on eosinophils, basophils and mast
cells by blocking the production of inflammatory cyto-
kines and decreasing the activation of T lymphocytes by
the Langerhans cells, while pimecrolimus also inhibits
the release of inflammatory cytokines from mast cells
[72]. TIMs are indicated in children older than 2 years
suffering from mild/moderate AD (pimecrolimus) or
moderate/severe AD (tacrolimus) [4] and meeting one of
the following requirements: a) absence of response to
the first-line therapy with topical corticosteroids; b) con-
traindications to treatment with topical corticosteroids;
c) side effects induced by the use of topical corticoste-
roids, such as skin atrophy or telangiectasia; d) necessity
of a long-term maintenance therapy [70]. Tacrolimus is
available as in ointment: in children ages 2 to 15 years
the 0.03 % formulation is indicated, while in patients
ages 16 years and older the 0.1 % formulation is indi-
cated. Pimecrolimus is available as a 1 % cream and has
lower percutaneous absorption than the tacrolimus oint-
ment. TIMs should be applied twice a day for 2–3
weeks, then once a day until resolution of the skin le-
sions and itch symptoms. If there isn’t any improvement
after 2 weeks of treatment, alternative therapeutic op-
tions must be considered. The proactive therapy illus-
trated for TCS can be also adopted for TIMs; the
patient’s clinical response should be re-evaluated after12 months to decide whether to continue [4, 74]. If re-
lapse occurs, the therapy can be restarted with two ap-
plications per day. Any lymphadenopathy should be
noted before starting therapy and monitored throughout
therapy [75]. The use of TIMs is contraindicated in pa-
tients with primary and/or acquired immunodeficiency,
suspected bacterial or viral infection, eroded and/or ex-
uding lesions, or significant sun exposure. Pimecrolimus
and tacrolimus can cause an initial and transient burning
sensation and/or itching at the site of application, espe-
cially if the eczema is in its acute phase; therefore pa-
tients should always be warned about the possibility of
these effects in order to increase their adherence to
treatment. Initial simultaneous treatment with cortico-
steroids can be considered to reduce the occurrence of
burning or itching. In the literature, cases of allergic
contact dermatitis and granulomatous rosacea-like reac-
tions are reported as adverse effects following the imple-
mentation of TIMs. Labial melanosis may also be noted
following the use of tacrolimus 0.1 % ointment [4, 76].
Several studies showed that intermittent or continuous
use of TIMs did not cause systemic immunosuppression
or increase the risk of bacterial or viral infections during
five years of follow up [4, 77]. In 2006, the Food and Drug
Administration reported the potential carcinogenicity of
TIMs after a few reports of skin cancer and lymphoma in
patients treated with TIMs. However, surveillance studies
conducted on the drugs showed that the number of malig-
nancies in patients with TIMs is lower than in the general
population, and a surveillance study on the pediatric
population showed that the prevalence of malignancies in
children treated with TIMs is comparable to that in the
general pediatric population [77, 78]. Monitoring of tacro-
limus and pimecrolimus blood levels is not currently rec-
ommended for the topical treatment of AD [4].
Summary box
 TIMs are a second-line therapy for AD.
 Tacrolimus ointment is used for moderate/severe
forms:
– 0.03 % formulation for patients aged 2–15 years;
– 0.1 % formulation for patients ≥ 16 years.
 Pimecrolimus 1 % cream is indicated for
mild/moderate AD in patients ≥ 2 years.
 Contraindications to the use of TIMs:
– <2 years old;
– congenital or acquired immunosuppression;
– known or suspected infection;
– eroded and/or exuding lesions
– significant sun exposure.
Wet-wrap dressing
Wet dressing, or wet-wrap therapy, consists of the appli-
cation of a topical medication followed by bandaging
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which is moistened and the second of which remains
dry [79]. After a brief 5-min bath with warm water, the
skin is patted dry, and then the topical medication is ap-
plied. Subsequently, the first layer of gauze is moistened
with warm water, excess liquid is squeezed out, the moist
gauze is applied to the skin, and then a second dry bandage
is applied. If possible, the moistening of the first layer can
be repeated every 2–3 h throughout the day after removing
the dry layer. Steam can be used to moisten the first layer,
but thorough cleaning of the vaporizer is recommended.
The most suitable topicals for this treatment are flutica-
sone propionate, methylprednisolone aceponate, mometa-
sone furoate, hydrocortisone acetate, or prednicarbate
mixed with a hydrophilic emollient to 10 % dilution (1 part
of steroid and 9 parts of emollient) for the body or a 5 %
dilution for face [80–85]. Latex-free tight bandages and or
elastic can be applied for 3 to 24 h at a time. Washable
bandages can be used, but daily bandages are preferred.
Wet-wrap dressing is a second-line treatment recom-
mended for severe or refractory AD in patients older than
6 months of age [80, 81, 86]. No precise guidelines exist;
effectiveness and the side effects are variable and depend
on the age of the patient, the topical used, the time of oc-
clusion, and the duration of treatment. The duration of
treatment is variable from 2 to 14 days. The major results
are obtained during the first week of treatment. Particular
caution is necessary when applying TCS in patients at pu-
berty, due to increased risk of developing striae distensae.
The most dangerous side effect is systemic absorption of
topical steroid, with transient increase in cortisol levels.
Other possible side effects are folliculitis, bacterial or viral
superinfection, and chills during the application of the wet
layer if the water is not hot enough. Adherence and suc-
cess can be increased through educational training [87].
Summary box
 Wet dressing consists of a double layer of gauze or
tubular dressings, the first of which is moistened,
while the second layer remains dry.
 Wet wrap therapy is a short-term second-line therapy
indicated for AD that is severe or resistant to topical
treatments in patients older than 6 months of age.
 Topical steroids are used diluted with emollients to
10 % for the body and 5 % for the face.
 The most dangerous side effect is systemic
absorption of steroid.
Systemic therapies
Systemic corticosteroids
Systemic corticosteroids have only a limited role in the
therapeutic management of severe or difficult-to-control
AD, both in children and adults [88–92]. Despite their
anti-inflammatory effect, these agents do not act directlyon the recovery of the skin barrier and can cause several
significant side effects [88]. Often, a rebound effect, or
relapse, occurs after their suspension. Studies supporting
their effectiveness are few and the study populations are
small. In fact, there is only one placebo-controlled study
by Schmitt et al. [89] that evaluates the effectiveness of
oral prednisolone and cyclosporine vs. placebo in pa-
tients who continued their topical therapy (emollients
and steroids). Only 1 patient out of 27 taking systemic
corticosteroids showed persistent remission (improve-
ment > 75 % in baseline SCORAD after 2 weeks of oral
steroids and 4 weeks of follow-up). This study was
stopped for the appearance of significant eczema flares
in the group treated with prednisolone. A recent review
of systemic treatments for AD [90] identified only two
other randomized controlled trials evaluating the efficacy
of systemic corticosteroids in children. The first work
evaluated the effectiveness of a 4-week therapy with
beclomethasone dipropionate in 26 children with severe
refractory eczema and found that the average SCORAD
was reduced by 22 % without serious adverse effects
[91]. In the second study [93], children were treated for
two weeks with oral flunisolide, and eczema severity was
reduced by an average of 39 % with no relapses during
the 3 weeks following discontinuation. However, the
quality of both of these studies is very low, and neither
studied methylprednisolone, which is the corticosteroid
most widely used in clinical practice. In an open study
of 7 children with very serious unresponsive eczema,
methylprednisolone was administered through IV bolus
at the dose of 20 mg/kg/day for 3 days [94]. Skin lesions
and itching improved for a few months without notable
side effects apart from a significant but transient lym-
phopenia. The Practical Allergy (PRACTALL) Consen-
sus Group guidelines [95] published in 2006 suggested
that patients with acute flares may benefit from a short
course of systemic corticosteroids, but their long-term
use, especially in children, should be avoided. Therefore,
the routine use of systemic corticosteroids in children is
not recommended. Short courses of therapy may be of-
fered in special situations, such as a severe exacerbation
widely affecting the body surface with intense itching, a
transition period before starting systemic non-steroidal
immunomodulatory drugs, or in the presence of comor-
bidities such as a severe asthma exacerbation [96–98].
Summary box
 The few available studies support a limited role for
systemic corticosteroids in the management of
severe AD in children.
 Exacerbation of symptoms often occurs after
discontinuation of systemic steroids.
 Long-term use of systemic steroids may cause
significant side effects.
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Systemic antimicrobials
Alteration of the skin barrier and defects of innate im-
munity predispose patients with AD to the complication
of infections, mainly bacterial but also fungal and viral.
Bacterial infections
S. aureus, and secondly S. pyogenes, are the most com-
mon causes of bacterial superinfections (see Chapter 1.3
“Topical antimicrobials”). Over all, S. aureus can be iso-
lated from up to 90 % of eczematous skin lesions.
Colonization with S. aureas is less common in children
younger than 2 years of age (50 % of lesions). The dens-
ity of the bacterial colonies tends to increase with the
clinical severity of atopic dermatitis [99]. However, treat-
ment with systemic antibiotics should be reserved for
clear evidence of bacterial infection [92, 97, 100–102].
The presence of bacterial colonies without clinical signs
of infection does not warrant a systemic antibiotic [97,
103] (strength of recommendation B, level of evidence II
[97]). Bacterial culture is not routinely required for anti-
biotic selection [104]. Uncomplicated bacterial infec-
tions, including those caused by staphylococci [105], can
be treated with a beta-lactam antibiotic for 7–14 days.
The first choice antibiotic is flucloxacillin (available only
in tablet form in Italy); alternatives include amoxicillin
and clavulanic acid or first- or second-generation cepha-
losporins such as cefuroxime and cefixime. Clindamycin
(available only in tablet form in Italy) or macrolides can
be used in subjects allergic to beta lactam; however,
macrolide resistance is quite high [104]. If antibiotic
therapy does not prove effective, compliance should be
evaluated and cultures with antimicrobial sensitivity pat-
terns should be obtained from both skin and nostrils.
The diagnosis may need to be re-evaluated [4]. In pa-
tients hospitalized with severe infections not responsive
to oral therapy, parenteral vancomycin, teicoplanin, or li-
nezolid (second line) should be administered [105]. In
case of recurrence, application of intranasal mupirocin
twice a day for 10 days and/or bathing in water contain-
ing chlorhexidine or sodium hypochlorite solutions
(0.005 %) are recommended to prevent or limit recur-
rences [106–109]. Other precautions for preventing in-
fection include avoiding sharing toiletries, using liquid
soap, and washing bedding weekly [107, 110].
Viral infections
Infection with HSV occurs in 3 % of patients and may
cause systemic complications (eczema herpeticum,
Kaposi’s varicelliform eruption) if not diagnosed and
treated early. Generally, the infection is localized to the
face and limbs, but it can be diffuse and accompanied byfever, lymphadenopathy, keratoconjunctivitis, or bacter-
ial superinfection. Associated meningoencephalitis is un-
common [111]. Careful clinical observation is required
to detect the characteristic clinical signs of umbilicated
2–4 mm diameter vesicles, which are often confluent
and covered by serous, yellowish crusts [112]. Other
conditions commonly included in the differential diagno-
sis include impetigo and more rarely “eczema coxsack-
ium,” which does not require systemic treatment [113].
Children with eczema herpeticum require treatment with
acyclovir as early as possible. The drug is typically admin-
istered orally but can be given intravenously if fever or
systemic symptoms are present [104, 114, 115] (strength
of recommendation C, level of evidence II [97]). Early use
of this treatment has reduced mortality to zero [114, 116].
Treatment with calcineurin inhibitors is contraindicated
during the acute phase [114]. Relapses occur in about
15 % of cases [117].
Fungal infections
The possibility of Malassezia restarting AD during ado-
lescence [118, 119] via an immunological mechanism
has been described in the literature. Malassezia may be
implicated in AD affecting the head and neck and not
responsive to the conventional therapy. In this subset of
cases, oral treatment with itraconazole, ketoconazole or
fluconazole has proven effective [120–122].
Summary box
 Treatment with systemic antibiotics should be
reserved exclusively for clear signs and symptoms of
bacterial infection, not simple bacterial colonization.
 The first-choice antibiotic is a beta-lactam:
flucloxacillin, amoxicillin and clavulanic acid or
cephalosporins active on S. aureus, such as cefuroxime
and cefixime.
 Additional treatment with intranasal mupirocin or
baths with an antiseptic such as sodium hypochlorite
can be useful to prevent or limit recurrence.
 Children with eczema herpeticum due to HSV
require systemic therapy with acyclovir as soon as
possible.
 In teenagers or others with AD localized to the head
and neck that does not respond to therapy, the
presence of Malassezia should be considered and an
oral antifungal such as itraconazole may be
administered.
Systemic immunosuppressant agents
Systemic immunosuppressants represent a valid thera-
peutic option for severe, widespread and refractory
forms of AD, since systemic corticosteroids have a lim-
ited role in the long-term therapeutic management [92].
Systemic immunosuppressants should be considered if
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child’s quality of life. However, therapy with systemic
immunosuppresants should be restricted to specialized
centers. There are few randomized controlled trials com-
paring systemic therapies, so assessing the relative effi-
cacy of each agent is difficult. Most of the literature
suggests the use of cyclosporin, but azathioprine and
methotrexate are also recommended.
Cyclosporine
Cyclosporin A (CsA) is an immunosuppressive drug
which acts directly on the immune system by inhibiting
T-cell function [123, 124] and is indicated in the treat-
ment of several skin diseases [125]. Its use in AD is
based on evidence that AD results from the activation of
a T-cell mediated inflammatory response of the skin
(with a prevalence of Th2 response in the acute phase
and Th1 in the chronic phase) [126]. The role of CsA in
patients with severe AD that is refractory to conven-
tional therapies is now confirmed (strength of recom-
mendation B; level of evidence I-II [97]). The drug has
shown considerable effectiveness in terms of reduction
of clinical extension of the lesions, reduced itching and
sleep deprivation scores, and improved quality of life
[96, 127, 128]. However, 10 clinical trials have detected a
rapid relapse of the disease within 8 weeks of discon-
tinuation, with clinical scores returning to pre-treatment
levels [129]. A recent study confirmed these findings,
with a relapse rate of 42 %, especially in patients who
had undergone short-course therapies [128]. CsA can be
administered with high- or low-dose regimens and short-
or long-term duration. Traditionally, an initial dosage of
5 mg/kg/day (up to 7 mg/kg/day according to some au-
thors) is recommended for the first 2 weeks of treatment,
followed by a maintenance dose of 1.5–3 mg/kg/day for a
total period of 6–12 months [96]. Unfortunately, there is
no evidence regarding the efficacy and safety of long-term
therapy with CsA. However, in the short term, higher
doses seem to be more effective in obtaining a rapid clin-
ical response [130]. After an induction period, intermittent
short-course therapy has been used to minimize risks
without losing clinical benefits [131]. The side effects of
CsA have led many physicians to advise regimens with the
lowest effective dose for each patient [128, 130]. CsA has
many reversible side effects, ranging from mild (headache,
hypertrichosis, gingival hyperplasia, paresthesias), with a
weekly rate between 1 and 28.2 % [96], to severe (hyper-
tension, kidney failure), with a weekly rate between 0 and
2.2 % [130]. CsA treatment requires careful monitoring of
blood pressure and renal function, and abnormalities war-
rant a reduction or suspension of therapy. However, sev-
eral clinical trials have shown that the tolerability profile
of this agent is better in children than in adults, with rare
severe side effects in childhood [132–134]. Currently,there is no evidence of increased risk of lymphoprolifera-
tive diseases with prolonged CsA treatment of AD [127].
In conclusion, the current guidelines recommend CsA as
the first-choice drug for severe AD refractory to topical
first- and second-line treatments [112]. Nevertheless, cau-
tion is always advised in the pediatric age group, and
short-term therapy is preferred [132].
Azathioprine
Azathioprine (AZA) is a purine analog which inhibits
DNA synthesis, with preferential action on fast dividing
cells, such as B and T cells during the inflammatory
phase. Data suggests benefit in the pediatric population
[135, 136], but the dosage and optimal duration of ther-
apy still need to de defined (strength of recommendation
B, level of evidence II [97]). The metabolism is of AZA
is directed towards the activity of thiopurine-
methyltransferase (TPMT), the main enzyme of thiopur-
ine, of which different genetic polymorphisms affecting
its action have been described. Myelotoxicity is associ-
ated with low TPMT activity [137]. The therapeutic
range of AZA for AD is variable between 1 and 4 mg/kg
daily [97], with 2.5 mg/kg daily being the most com-
monly used dose.
In Italy AZA is available only in 50 mg-tablets. Some
patients may need prolonged treatment up to 12 weeks
to obtain a full clinical remission. To monitor the possible
adverse effects, TPMT activity (if available), peripheral
blood counts, and liver enzymes should be measured be-
fore and during treatment [138]. Concomitant photother-
apy is not recommended, due to increased risk of DNA
damage and carcinogenesis, particularly with the exposure
to UVA [138].
Methotrexate
Methotrexate (MTX) is an antifolate metabolite capable
of blocking synthesis of DNA, RNA, and purines. It
probably acts by inhibiting T-cell function. In recent
years, several studies have highlighted the effectiveness
of MTX in adult AD without serious side effects [139]
(strength of recommendation B; level of evidence II
[97]). Few controlled studies are currently available in
pediatric age; thus, the use of MTX is mostly limited to
clinical research [140, 141]. However, the use off-label
of MTX can be considered in the absence of thera-
peutic alternatives [140]. The therapeutic dose in chil-
dren is between 0.2 and 0.7 mg/kg/week, and the
duration of therapy is of 10–16 weeks. Folate supple-
mentation is always recommended during MTX treat-
ment to reduce gastrointestinal and bone marrow
toxicity. In an open randomized trial involving children
with severe AD refractory to topical treatments and
phototherapy, MTX and CsA had equivalent effectiveness,
reducing SCORAD by 40 % after 12 weeks [141].
Table 5 Classification of antihistamines (from AIFA repository 2015)
First-generation
H1 antihistamines
Second-generation
H1 antihistamines
Active metabolites
of second-generation
H1 antihistamines
(third- generation
H1 antihistamines)
Alkilamines: Chlorpheniramine Cetirizine Levocetirizine
Dimethindene Loratadine Decarboetoxiloratadine
or Desloratadine
Ethanolamines:
Diphenhydramine
Ebastine Norastemizole
Ethylenediamines: Thonzylamine Acrivastine Fexofenadine
Phenothiazines: Promethazine Astemizole
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and liver and kidney function should be strictly moni-
tored during treatment. Screening for hepatitis B and
C as well as chest radiography should be performed
before starting treatment.
Biological drugs (soluble receptors, monoclonal anti-
bodies and cytokines such as recombinant interferon,
anti-TNF, and inhibitors of the IgE/IL-5 pathway) are
relatively new and lack sufficient data for recommenda-
tion in clinical practice.
Summary boxPiperazines: Hydroxyzine Terfenadine
Piperidines: Ciproeptadina Azelastine
Oxatomide Mizolastine
Intermediate degree of
lipophilicity
Bilastine
Ketotifen Rupatadine
Levocabastine Use of immunosuppressant agents in AD should be
restricted to specialized centers.
 CsA is an immunosuppressive drug recommended
as first-choice therapy for severe AD refractory to
first- and second-line topical treatments.
 CsA is effective in reducing clinical scores and
improving children’s quality of life, but frequent
relapse of AD after the end of treatment has been
reported.
 Blood pressure and renal function must be carefully
monitored during CsA therapy
 AZA and MTX may represent therapeutic options
for severe and refractory AD, but controlled studies
defining the optimal dosage and duration of therapy
are still lacking.
Antihistamines
Oral antihistamines (H1-receptor antagonists) block the
effects of H1-receptor stimulation (vasodilation, ery-
thema, edema) and have been included in the guidelines
for AD treatment for a long time. However, their useful-
ness is controversial and debated [104, 142]. In general,
the recent literature permits a short course in order to
control itching. Some authors allow systemic therapy
with H1 antihistamines only in patients whose AD is as-
sociated with symptoms of allergic rhino-conjunctivitis
[97, 143, 144]. The pathogenesis of itch is very complex
and related not only to the release of histamine [145],
but also to the involvement of several other mediators
such as proteases, gastrin-releasing peptide, substance P
and IL-31. Experimental data show that the receptor
PAR-2, present on keratinocytes and other skin cells and
activated by proteases, plays a predominant role in me-
diating itch [146]. First-generation H1 antihistamines
have lipophilic properties, which allow them to cross the
blood–brain barrier and exert a subsequent sedative
effect. Second-generation antihistamines have less li-
pophilicity and, therefore, do not cross the blood–
brain barrier and are less sedating (Table 5). Due to
the sedative properties of first-generation H1 antihis-
tamines, both pediatricians and dermatologists allow
short-term treatment with this medication to improvethe patient’s quality of sleep [147]. On May 2014
the EMA observatory (European Medicines Agency)
launched a review of drugs containing the antihista-
mine hydroxyzine because of possible adverse effects
on the electrical conduction system of the heart
[148]. In addition to H1 and H2 receptors, which are
mainly located in the gastric mucosa, H3 receptors
are expressed the central and (to a lesser degree) per-
ipheral nervous system, and H4 receptors play a role
in regulation of immune and inflammatory responses
[149, 150]. The first results of the Early Treatment of
the Atopic Child (ETAC) study [151], a multicenter
trial on the efficacy of anthistamines (cetirizine/levo-
cetirizine) to change the natural history of atopic dis-
eases, published in 1998, showed good tolerability
[152], but subsequent analysis of the benefit-risk-cost
relationship was unfavorable, without no benefit in
the prevention of asthma. Studies on the role of H4
receptors and their antagonists are ongoing, focusing
on possible effects on the inflammatory response and,
thus, on immune disorders, including AD The expres-
sion of H4 receptors on dendritic cells and keratino-
cytes favors a TH2-type response and the production
of various mediators of inflammation, including IL-31,
involved in the complex genesis of pruritus [153]. Fi-
nally, the topical use of H1 antihistamines is not rec-
ommended due to the risk of absorption and contact
allergy [4].
Summary box
 There is no evidence to support widespread use of
antihistamines in AD.
Galli et al. Italian Journal of Pediatrics  (2016) 42:26 Page 12 of 25 Short-term and intermittent courses of sedating
(first-generation) antihistamines can be used in
children if itch strongly affects quality of sleep.
 Topical use of antihistamines is not recommended
due to risk of absorption and contact allergy.
Phototherapy
Phototherapy is a second-line treatment, used when the
AD is not controlled with emollients, topical steroids
and TIMS [92, 154]. Numerous studies have demon-
strated the efficacy of phototherapy in AD, both in the
acute and the chronic phase [97, 155]. Currently avail-
able devices emit spectra of UVA and UVB radiation, es-
pecially narrow-band UVB (UVBTL01 311–313 nm) and
UVA1 (340–400 nm). Phototherapy with UVA1 can be
carried out with high (130 J cm2), medium (50 J cm2) or
low -dose (10 J cm2). The mechanism of action of UV in
AD is not completely understood, but an antimicrobial
effect that reduces colonization of S. aureus and induces
cytokine production with anti-inflammatory and im-
munosuppressive properties is assumed. Phototherapy
with UVBTL01 is indicated in moderate forms of
chronic AD, while high-dose UVA1 is preferred for
severe and exuding AD. Phototherapy with UVBTL01
is most widely used due to availability, tolerability, ef-
fectiveness, and low carcinogenic risk in long-term
use [155, 156]. However, it is not indicated in chil-
dren younger than six years. To date, no clear guide-
lines for phototherapy in AD are available, and
patients typically follow protocols for psoriasis (2–3
sessions per week). The starting dose is calculated
based on the minimum erythema dose or Fitzpatrick
skin phototype. Emollients may improve the effective-
ness of treatment and topical steroids can be used to
better control eczema before starting the photother-
apy. Data on the duration of remission and compar-
ing various approaches are missing. Common side
effects at the beginning of the treatment include itch-
ing, burning, erythema, and folliculitis. The long-term
risk of UVBTL01 phototherapy is unknown; neverthe-
less, its safety profile has been proven in patients
with psoriasis.
Summary box
 Phototherapy is a second-line treatment to be used
when the AD is not controlled by other therapies.
 Narrow-band UVB (UVBTL01) is most commonly
used and is indicated for children six years of age
and older.
 Psoriasis treatment regimens are followed, with 2–3
sessions per week for a duration of a few months,
depending on clinical response.
 Long-term carcinogenic effects have not been
reported.Allergen immunotherapy
Theoretically, allergen immunotherapy (AIT) may repre-
sent an additional therapeutic option for a subgroup of
patients in which interventions of environmental pre-
vention against mites (discussed below) has not led to
significant improvement. The principle of AIT is admin-
istering increasing doses of clinically relevant allergen(s)
in order to induce immunological tolerance in a sensi-
tized patient [157, 158]. The therapeutic efficacy of AIT
has been clearly demonstrated in allergic asthma, rhinitis
and hymenoptera venom allergy [159–162]. Despite this,
AIT has not been shown to be an effective treatment for
AD. In fact, while the 2012 European guidelines sug-
gested a potential benefit of AIT in a select group of
patients with coexistent allergic sensitization and AD
sensitization, the latest AAD guidelines published in
2014 do not mention this therapeutic option [97].
For many years, AIT had not been considered in the
treatment of AD, since it was believed to be associated
with a worsening of the disease. However, the latest
studies have found good tolerability of the treatment in
most of patients [163–166]. Since 1974, several clinical
studies on the treatment of AD with AIT have been per-
formed, some of which included pediatric subjects
(Table 6). Otherwise, few controlled studies are available.
Authors of recent reviews conclude that there is no evi-
dence to recommend the use of AIT in the treatment of
AD [167, 168]. However, some authors identify as poten-
tial candidates for AIT a subgroup of highly selected pa-
tients with the following characteristics: a) IgE-mediated
sensitization (in particular to house dust mites, but also
birch and grass pollens); b) severe AD (SCORAD > 50);
c) Atopy Patch Test positive for the eliciting allergen. A
recent meta-analysis of 8 RCTs including adult and
pediatric patients found that AIT was effective, but
subgroup analysis of the four studies with exclusively
pediatric populations did not show significant benefits
[164]. Analysis of the safety profile of the treatment
found no significant difference between patients and
controls, and no severe adverse reactions were re-
ported in any of the included studies. Although the
meta-analysis favored the efficacy of AIT for AD, the
validity of meta-analysis’s methodology has been ques-
tioned [169]. Randomized clinical trials and observa-
tional long-term placebo-controlled studies evaluating
the “disease modifying” effects of this treatment are
lacking. Therefore, its therapeutic indication in pa-
tients affected exclusively by AD remains controver-
sial [3].
Summary box
 Although its safety profile is favorable, AIT is not an
appropriate therapeutic option for all patients
suffering from AD.
Table 6 Observational studies and randomized controlled trials (RCTs) on allergen immunotherapy (AIT) which included pediatric
patients with atopic dermatitis (AD)
Study Study
design
Patients n
(age, yrs)
Allergen Route Duration
(months)
Outcome Adverse reactions
% AIT compared
to control group
Efficacy
Kaufman et al.
1974 [271]
qRCT
DBPC
52 (2–47) Danders SCIT 24 Success of the
treatment (Physician)
Systemic: NA Positive in 81 %
of treatment
group vs. 40 %
of controls
HDM
Moulds Locals: 50 vs 40
Pollens
Warner et al.
1978 [272]
RCT DBPC 20 (5–14) HDM SCIT 12 Success of the
treatment (Patient)
Systemic: NA Positive
Locals: NA
De Prisco de
Fuenmayor et al.
1979 [273]
Obs. 15 (6–14) Airborne
allergens
SCIT - Clinical assessment Occasional
exacerbation of AD
Positive in 60 %
of patients
Ring 1982 [274] PC 2 twins (10) Pollens
(grasses)
SCIT 24 Clinical assessment
sIgE (grasses) Total IgE
Occasional
exacerbations of
eczema in SCIT
patients
Positive
Seidenari et al.
1986 [275]
Open 63 (4–45) SCIT 6–24 Clinical assessment Occasional mild
exacerbation
Positive in 65 %
of patients
Glover et al.
1992 [276]
RCT DBPC 24 (5–16) HDM SCIT 8 (phase I) Success of the
treatment
Systemic: 0 vs 8 Uncertain with a
possible positive
effect of prolonged
treatment (phase II)6 (phase II) (Patient) Locals: NA
Heijer et al.
1993 [277]
Obs. 93 (6–66) Airborne
allergens
SCIT 39 Clinical assessment Asthma, RC, fever,
fatigue, itching,
dizziness
Positive
Total IgE
Galli et al.
1994 [278]
RCT PC 34 (0.5–12) HDM SLIT 36 Success of the
treatment (Physician)
Systemic:0 Negative
Locals: 6.3 vs 5.6
Trofimowicz et al.
1995 [279]
Obs. 22 HDM SCIT 36 Clinical assessment - Positive in 75 % of
patients treated with
AIT for HDM and up
to 80 % of patients
treated with AIT for
pollens
Pollens
Zwacka et al.
1996 [280]
Controlled 212 (6–15) Airborne
allergens
SCIT vs
SLIT
24 Clinical assessment - Positive
(both SLIT and SCIT)
Total IgE
Czarnecka-Operacz
et al. 2006 [281]
RCT DBPC 66 (5–44) HDM SCIT 48 Success of the
treatment (Physician)
- Positive
- 37 AIT Pollens
-29 Controls
Pajno et al.
2007 [282]
RCT DBPC 56 (5–16) HDM SLIT 18 SCORAD (Physician) - Local reactions
in 7 SLIT patients
Positive only in
patients with mild
to moderate AD,
not in those with
severe
- Itching and
erythema in 2
SLIT patients
-28 AIT Pharmacotherapy
-28 Controls
Cadario et al.
2007 [283]
Obs. 86 (3–60) HDM SLIT 12 (at least) SCORAD No severe
reactions
Positive
Total IgE and sIgE
Bussmann et al.
2007 [284]
Obs. 25 (5–65) HDM
(allergoid)
SCIT 7 SCORAD - Positive
sIgE; sIgG4
IL/mediators
Nahm et al.
2008 [285]
Obs. 20 (7–58) HDM SCIT 12 Clinical assessment None relevant Positive
SCORAD
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Table 6 Observational studies and randomized controlled trials (RCTs) on allergen immunotherapy (AIT) which included pediatric
patients with atopic dermatitis (AD) (Continued)
Kwon et al.
2010 [286]
Obs. 20 (6–33) HDM SCIT 12–60 Clinical assessment No exacerbations Positive
sIgE (DP)
Total IgE
Chemokines
qRCT quasi-randomized controlled trial, DBPC double blind placebo controlled, HDM house dust mite, Obs. observational, PC placebo controlled, SCIT subcutaneous
immunotherapy, SLIT sublingual immunotherapy, DP Dermatophagoides pteronyssinus
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small number of controlled randomized clinical
trials and the high heterogeneity of the published
works.
 AIT is most strongly indicated in a sub-group of
patients with the following characteristics:
sensitization to dust mites, clear correlation
between allergen exposure and clinical manifestations,
and severe AD.
Non-pharmacological interventions
The role of foods
The link between AD and food allergy (FA), including
FA’s possible role in causing AD, remains controversial
[170]. Support for the causal link comes from the obser-
vation of immediate-type allergic reactions in children
with AD after the elimination and subsequent reintro-
duction of certain foods, especially cow’s milk (CM) and
hen’s egg [171–176]. Additionally, many studies have
shown that the more severe the AD [176–179] and earl-
ier its first appearance [180], the greater the association
with IgE-mediated FA comorbidity. The foods that most
often cause FA in patients with AD are CM, egg, peanut,
wheat, soy, nuts, and fish [179].
Although AD has proved to be a very complex and
heterogeneous disease, it is possible to identify two main
subtypes based on whether IgE levels are elevated (IgE-
associated/extrinsic AD) or normal (non-IgE-associated/
intrinsic AD). The latter, which is more common in
preschool-age children and adults [181, 182], is associ-
ated with a lesser risk of developing asthma. According
to Bergmann et al. [183], the patterns of clinical reac-
tions to food in patients with AD can be divided into
three groups: a) immediate-type reactions, usually IgE-
dependent, developing within 2 h and characterized by
urticaria, angioedema, rash, itching and possible involve-
ment gastrointestinal and respiratory tract; b) delayed-
type reactions that occur 6 to 48 h after the food intro-
duction, with typical areas of eczema and are typically
non-IgE mediated; c) mixed type, occuring in 40 % of
children with AD and positive food challenge [184]. In
1978 a double blind controlled crossover study by Ather-
ton et al. [185] first demonstrated an improvement in
AD following a diet without CM and egg. Subsequentstudies on patients with AD observed only immediate
symptoms after consumption of trigger foods, suggesting
a comorbid FA [172, 174, 176, 186]. Rowlands et al.
[187] were able to demonstrate a link between reintro-
duction of previously eliminated foods and late recrudes-
cence of AD only in one out of 17 children hospitalized
with severe AD. Other studies showing the onset of late
eczematous-type reactions not preceded by immediate
allergic reactions are scarce and of variable quality [175,
188]. The key question is whether food allergy in the
context of IgE-associated AD is an unrelated condition
or whether it can trigger or worsen AD. Another option
is that the food directly causes a delayed reaction. Row-
lands et al. [187] assert that although it is possible that
the food might induce a true eczematous lesion, this is
the exception rather than the rule.
Genetic predisposition that leads to abnormalities of
the skin barrier has been accompanied by an abnormal
immune response that makes the skin even more vulner-
able to environmental factors. Individuals with AD and
concomitant filaggrin (FLG) deficiency tend to have earl-
ier onset of the disease, which in turn is more severe
and persistent and more commonly associated with al-
lergic sensitization [189–191]. It should however be
noted that all patients with AD exhibit a barrier defect,
but not all patients with FLG deficiency have AD.
In particular, a link has been observed between FLG
gene mutation and peanut allergy [192]: the FLG defi-
ciency allows food allergens to penetrate through the
skin, interact with the immune system, and induce FA.
In fact, although the sensitization to food classically hap-
pens through the intestines, Du Toit et al. [193] have
shown that peanut sensitization can occur without previ-
ous ingestion, by simply applying peanut dissolved in oil
to inflamed skin, and that early introduction decreases
the frequency of peanut allergy. Also, Fox et al. [194]
have found an association between environmental ex-
posure to peanut and risk of developing peanut allergy;
trace amounts of peanut can be found in furnishings or
on hands [195].
The above data recently has led to the suggestion to
overturn the pathogenic mechanism linking FA to AD:
as opposed to FA inducing AD, exposure of skin with a
barrier defect to a food may cause first a sensitization
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early consumption of food would induce, through the
gastrointestinal system, a food tolerance [199–201]. The
timing and the balance of dermal and/or intestinal ex-
posure would determine whether the child develops a
food allergy or a food tolerance [202]. This mechanism
has been confirmed in some mouse models, where the
abrasion of the skin and subsequent deposition of pea-
nut or ovalbumin leads to a significant specific IgE re-
sponse [203, 204]; this state, in turn, can result in a
clinically evident FA, as is the case with AD patients
whose skin is exposed to peanut oil [193], especially if
allergen doses are high. This new view of the problem
could be simplistic in that it attempts to export the pea-
nut model to other foods, in particular in CM, egg and
wheat. However, it is likely that the concentration in the
air of food allergens other than peanut is not as high as
the concentration of peanut and inhalant allergens.
Additionally, in AD patients, the dynamics of
sensitization to food allergens varies from food to food
[205]; peanut acts similarly to an inhalant allergen, with
a continuous increase in the concentration of specific
IgE over time, while CM- and egg-specific IgE tend to
decrease over time. Furthermore, the concentration of
food allergens present in mattress dust varies from food
to food [206]. Finally, it is known that children with AD
may be sensitized to egg [207] without ever having
ingested it [208]. The above is to emphasize that al-
though the skin of the subjects with AD may allow the
entry of food allergens, it is not the only point of entry
for food allergens.
FA is also seen in people without AD or other skin
damage [209]. In the study by Flohr et al. [210] of 619
exclusively breastfed children at 3 months of age, 154
(24.9 %) suffered from AD, but only 24 % of the babies
with AD had a FLG mutation (vs. 8.4 % of those without
AD). AD was found to significantly correlate with food
sensitization but not with the FLG mutation [210]. Flohr
et al. argue that since the children were breastfed and
there are few allergens in breast milk, sensitization had
occurred through the skin, not through the intestines.
This argument is consistent with the previous demon-
stration of peanut sensitization in AD patients by appli-
cation of peanut oil to the skin [193]. In our opinion,
this explanation seems forced since detection of consid-
erable quantities of heterologous proteins has been
widely demonstrated in breast milk from mothers of
both infants with AD as well as healthy infants [211]. It
would then require individual predisposition or specific
intestinal conditions to ensure that a protein first in-
duced sensitization and then caused a real FA.
In sum, lesional skin is one of the possible routes of
entry for allergens, as the direct contact of lesional skin
with peanuts and/or other foods (directly spread on theskin or through contact with contaminated hands) may
facilitate the occurence of sensitization. Finally, it must
be considered that allergic inflammation of any type may
damage the same skin barrier and inhibit the formation
of FLG [212].
Summary box
 AD is a multigenic and multifactorial disease often
associated with increased production of total and/or
specific IgE. This may be associated with
sensitization to foods, inhalant allergens, or both.
 Allergic sensitization may occur through the
gastrointestinal (breast milk) or the transcutaneous
route.
 Allergic inflammation can alter the skin barrier by
reducing the production of FLG.
 If a child with AD is suspected of having a FA,
assess whether there is a food sensitization and
whether symptoms (shock, urticaria, persistent
diarrhea, asthma) require an elimination diet.
Generally, it is preferable not to eliminate foods in
sensitized patients without relevant immediate
reactions.
 In subjects with moderate-severe AD, skin testing,
particularly for the egg, may be justified. If positive,
egg should be introduced in a protected environment,
for the risk of immediate allergic reactions.
 In the event that appropriate therapy with emollients,
topical corticosteroids and/or systemic treatments is
ineffective and there is suspicion for a food a trigger, a
short elimination diet and subsequent food challenge
may be attempted.
 However, some advise against attempting elimination/
reintroduction diets due to the possibility that
reintroduction of the suspect food could cause a
severe allergic reaction.
Role of the environmental triggers
Several environmental factors seem to play a role in AD,
particularly in exacerbations. In addition to mechanical
and chemical irritants (e.g. wool, irritant soaps, toiletries
containing alcohol or perfumes), indoor allergens, environ-
mental pollutants, and climatic changes may play a role.
House dust mites
House dust mites, D. pteronyssinus and D. farinae, have
been recognized as the main source of household aller-
gens, especially in temperate climates [3, 213].
Mites release several allergens into the environment,
including cysteine-protease (Der p 1, Der f 1), serine
proteases (Der p 3, 6 and 9), glycosidases, carbohydrate-
binding proteins, calcium-binding proteins, and cyto-
skeletal and muscle proteins [214]. In addition to the
classic route of allergic sensitization, there is evidence
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pro-inflammatory non-IgE mediated activity directly on
the epithelial barrier, both stimulating receptors of the
innate immune system and releasing pro-inflammatory
cytokines and interleukins [214–216].
Several studies have also observed a correlation be-
tween the degree of exposure to mite allergens during
early childhood and risk of allergic sensitization [217–
219]. In some patients with AD, it has been documented
that exposure to dust mites by direct contact or inhal-
ation can exacerbate the disease [220]. However, the role
of this exposure in the pathogenesis of AD remains con-
troversial, since positive correlations were mainly in obser-
vational studies [221]. In addition, studies assessing the
effectiveness of prophylactic anti-mite environmental in-
terventions (e.g. anti-dust mite covers), showed reduction
in the concentration of dust mite allergens in domestic
areas but did not show reduced risk of allergic
sensitization or reduced AD severity [222–224]. However
in some cases, especially in patients with more severe AD,
a significant improvement in clinical AD scores due to
stringent prophylactic environmental measures, was
shown [225]. Similar but less significant results have been
observed in two additional studies, one of a pediatric
population with AD and the other of an adult population
with AD [226, 227]. Studies on the relationship between
AD and the environment have not yet confirmed the pre-
cise role of environmental dust mites in AD. However,
one of the possible reasons for discrepancies is the lack of
homogeneity in the prophylactic measures used [228–230].
Currently, recommendations for mite prophylaxis suggest
the simultaneous application of multiple interventions,
such as reducing the relative humidity in the house (the
main risk factor for mite growth) to around 50 %, using
anti-mite covers, eliminating the main sources of allergen
accumulation (e.g. carpets, rugs, curtains, plush), washing
pillowcases weekly at high temperatures (about 60 °C),
and vacuuming with a machine containing a HEPA filter
capable of removing allergens [228]. The American Acad-
emy of Dermatology recently recommended considering
anti-mite prophylactic measures (especially anti-mite pil-
lowcases and mattress covers) for AD patients sensitized
to dust mites and insufficiently controlled by topical
therapy [97].
Pets
In addition to mites, pet allergens have been proposed
to play a role in AD. However, at the present, the rela-
tionship between early-life exposure to these allergens
and the appearance of allergic sensitization and allergic
diseases is still controversial. Recent cohort studies indi-
cate that the first year of life is a critical period, during
which exposure to pets, especially dogs, may reduce the
risk of developing allergic sensitization and AD later inlife [231]. The results are not homogeneous and are
complicated by confounding factors, such as family his-
tory of atopy and exposure to dog and cat allergens out-
side the home [232]. Therefore, at present no guidance
exists about keeping or removing pets already living in
the house in order to prevent development of allergic
diseases including AD [233].
Environmental pollutants
Increasing evidence shows a correlation between the
level of environmental pollutants and respiratory aller-
gic diseases, especially in regions undergoing rapid
industrialization [234]. However the role of exposure
to such pollutants in AD has not been defined, as only
few prospective studies have documented an association
between AD and concentrations of pollutants, especially
those produced by vehicular traffic (nitrogen oxide, par-
ticulate matter [PM]) [235]. However, recent evidence
seems to support the role of environmental pollutants in
exacerbating AD. Higher concentrations of PM 10 and
volatile organic compounds have been linked with AD ex-
acerbations [236], while clinical improvement was ob-
served with increased cleaning in kindergarten classrooms
and reduced environmental PM 10 [237].
Climatic influences
Recent attention has been paid to the role of climatic
variations, which may affect differences in the preva-
lence of AD worldwide. Osborne et al. have docu-
mented a lower prevalence of AD in Australian
children living in regions closer to the equator [238].
Similarly, Silverberg et al. have shown that the preva-
lence of AD in the United States is lower in the re-
gions with the highest solar exposure [239]. These
data support the hypothesis of a link between AD
and levels of vitamin D. On the other hand, a recent
prospective study observed that greater sun exposure
and elevated temperatures were associated with un-
controlled AD [240, 241]. Although such correlations
do not prove a causal effect, it is necessary to educate
the patient and family about the possible role of cli-
matic factors, with particular attention to exposure to
very high temperatures (both environmental and
household during the winter season), which can in-
crease sweating and water evaporation from the skin,
exacerbating dryness and skin irritation [240].
Summary box
 Avoid mechanical and chemical irritants (eg. wool,
irritant soaps, toiletries containing alcohol or
perfumes).
 Anti-mite prophylactic measures should be
recommended for AD patients sensitized to mites
and insufficiently controlled by topical therapy.
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keeping or removing household pets for the sake of
preventing sensitization.
 Emollient therapy should be adapted to climactic
characteristics (relative humidity, solar exposure,
temperature).
Textiles
In patients with AD, direct contact with certain textiles
with rigid fibers (e.g. wool or nylon) is a source of irrita-
tion [242], while the use of soft fabrics (e.g. knitted silk;
cotton, with or without silver enrichment) may reduce
the skin irritation [3, 243]. Soft fabrics reduce friction,
have transpiring properties and allow the absorption of
sweat and exudates, which are important in maintaining
the hydrolipidic film of the skin [244]. The effectiveness
of Dermasilk®, a new knitted silk fabric with antimicrobial
properties, has been evaluated in a very limited number of
controlled clinical trials. The studies have shown encour-
aging results, with improvement of clinical scores and re-
duction of disease recurrence during the maintenance
phase [244–247]. In a study of Gauger et al. [248], tissues
enriched with silver also were effective in improving AD
symptoms within 2 weeks of use. However, the risk of
percutaneous absorption of silver should be always
considered, especially in damaged skin [249]. ZnO-
functionalized texile fibers (BenevitZink+) also seem to
improve AD severity [250]. In view of the limited num-
ber of clinical studies carried out and the high cost of
these materials, the most recent American guidelines
conclude that there is limited evidence to support the
use of these textile products in treatment of AD [97]. In
any case, direct contact between irritating fabrics or
wool and the skin should be avoided.
Summary box
 Avoiding contact with irritating fabrics is essential
AD patients.
 The use of textile products with antibacterial action
must be confirmed by further studies.
Balneotherapy
Balneotherapy is the immersion of the body or parts of
it in bathtubs or pools of mineral water. Mineral waters
may be categorized as sulphurous, bicarbonate, sulphate,
carbonic, arsenical and ferruginous [251] and as hypo-
tonic, isotonic or hypertonic. Temperature may vary be-
tween 20 and 40 °C. To be considered “medical,” the
water must have a minimum concentration of ion and/
or gas to induce relevant clinical effects. The compos-
ition and threshold dose of the thermal water may vary
from one region to another and among health resorts
[252]. Among the mineral waters, calcium-bicarbonate
magnesium water is most indicated for AD treatment.For many years, Dead Sea waters have been used in the
management of skin disease, since they are the salitiest
on earth (salt content is 350 g/l vs. 40 g/l for most
oceans or seas [253]) and particularly rich in salts such
as MgCl2, CaCl2, KCl, and MgBr2. The presence the
CaCl2 gives to the Dead Sea waters [254] a slimy feeling.
The Dead Sea waters are very rich in magnesium, which
promotes cell maturation and keratinocyte differenti-
ation and is particularly useful in patients with psoriasis
[255]. It is also a natural moisturizer that can improve
the skin’s capability to retain water. Retrospective studies
have shown the benefit of the climate and the Dead Sea
salts for patients suffering from AD and other skin dis-
eases, in the absence of significant side effects [256]. Un-
fortunately, few studies have been published, and they
have been methodologically insufficient. The beneficial
effects of treatment with Avène water for 3 weeks were
evaluated in a observational study [257]; patients bathed
for 20 min at 32 °C and showered to remove scales
6 days out of 7 for three consecutive weeks. At the end
of the therapy, the clinical score of the AD improved sig-
nificantly with long-term benefits. An open randomized
controlled trial comparing the efficacy of the combin-
ation of baths of duration ≥ 4 min in a solution of 10 %
Dead Sea salts plus phototherapy (exposure to 15–30
min to UVB 311 nm) vs. phototherapy alone detected
greater clinical improvement in the group that bathed
with the Dead Sea salts [258]. Finally, an open random-
ized controlled trial [259] evaluated the efficacy of the
hot springs baths of Terme di Comano (Trento, Italy) in
104 children between 1 and 14 years with mild to mod-
erate AD. Patients were alternately assigned to balneo-
therapy or to topical corticosteroid treatment for
2 weeks. At the end of the study, significant improve-
ment in eczema severity and the quality of life was seen
in both groups. The group treated with corticosteroids
experienced more pronounced initial clinical improve-
ment, but after 4 months, the group receiving hydrother-
apy had significantly fewer and shorter exacerbations.
The effects of hydrotherapy are enhanced by coexisting
factors such as the relaxing spa environment [241],
climatotherapy (warm weather), sun exposure (light
therapy), and therapeutic education program [260].
Balneotherapy is generally not recommended during
acute eczema, especially in children. Contraindications
are febrile or exanthematous diseases and impetigini-
zation. After 5–7 days of treatment, a transient exacer-
bation of the disease (“spa reaction”) can occur; this
phenomenon is most likely to be observed if the
dermatitis is not well controlled, and it usually resolves
at the end of the treatment [259]. In conclusion,
balneotherapy is a possible adjuvant therapy in the
management of AD, but further studies are necessary
to confirm its efficacy.
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 Balneotherapy is possible adjuvant therapy in the
long-term management of the AD.
 Further randomized controlled studies are needed to
assess its effectiveness.
 The effects of hydrotherapy are probably enhanced
by other factors such as the relaxing spa environment,
the warm climate, increased sun exposure and
therapeutic education program.Educational interventions
The complexities of AD can be summarized as follows:
1) multifactorial etiopathogenesis; 2) chronicity; 3) early
age of onset; 4) involvement of the family system.
Both genetic and environmental factors contribute to
its complexity. The latter are considered an expression
both of the physical environment (such as health and cli-
mate) and the psycho-social system. Chronicity requires
that patients (depending on age) and their caregivers ad-
equately understand the disease and the required treat-
ment and comply with the programmed treatment [261].
The early age of onset (0–14 years), and the varying clin-
ical manifestations of AD at different stages of develop-
ment, require physician knowledge of the psycho-social
and relational implications of the disease so that inter-
ventions may be adapted accordingly. The family is a dy-
namic system that is critical in the emotional-affective
and educational development and psychological well be-
ing of the patient. A family dealing with a chronic dis-
ease, such as AD, requires multidisciplinary support
which can be summarized in the following three levels:
1) bio-pharmacological; 2) educational, pedagogical and
instructive; 3) psychological/psychotherapeutical. In fact,
in recent years, the scientific research on the treatment
of AD has shifted from the biomedical, technical and
“paternalistic” model toward a bio-psycho-social and
educational one.
Therapeutic education, as defined by the WHO
[262], allows us to provide not only technical informa-
tion about the disease and corresponding treatments but
also a customized plan developed in partnership with
the patient and the patient’s caregivers.
It is important to consider how emotional factors like
insecurity, inadequacy, anxiety, and depression affect
atopic patients [263]. Additionally, the family is afflicted
by both economic stress related to the cost of treatment
and by a significant psychological burden, which is par-
ticularly heavy in young and severely affected children
[264]. These factors may affect treatment compliance.
The Ideal Model of Intervention integrates different
theoretical and operational models, with participation of
a multidisciplinary team composed of the specialist
physician (Pediatrician, Allergist, Dermatologist), thepsychologist/psychotherapist, and other professionals,
such as nurses.
The specialist acts as the expert in therapeutic education
and first conducts a psychologically supportive educational
interview, covering:
 questions about the onset, history and evolution of the
disease, as well as challenges in adhering to treatment
 evaluation of symptoms, such itching and sleep
disturbance, by quantitative tools, such as the
Patient Oriented SCORAD (PO-SCORAD) [265]
and a Visual Analogue Scale of Pruritus;
 strategies for coping with itching and sleep
disturbances [266]
Discussing challenges with treatment compliance, itching,
and sleep allows for re-education about more effective
strategies and improves adoption of these strategies.
A second education-oriented interview can be con-
ducted by the broader team of physicians (dermatologist,
pediatrician, allergist), nurses and psychologist with spe-
cific objectives:
 teaching the recognition of skin lesions and the
application of topical medications, overcoming
corticophobia, preventing flare-ups
 demonstration by nurses of techniques for bathing,
applying topical medications while performing baby
massage, and bandaging. The aim is for bathing,
moisturizing, and dressing to be positive occasions
of play.
These sessions can be conducted as large group dem-
onstrations or, preferably, as smaller workshops, with
more opportunity for practical individualized demon-
strations [267].
After this phase, a psycho-diagnostic step may be of-
fered for the patient and parents if the family requests it
or if the staff believes it is indicated [268].
Psychotherapeutic Intervention for the patient is ne-
cessary when individual/family psychopathological suf-
fering is severe, as may be the case in severe AD. The
clinical assessment includes some psycho-diagnostic
testing for parents and patients over the age of 4 years,
which helps identify the most useful psychotherapeutic
intervention [269]. Psychotherapeutic intervention, pro-
vided by a professional expert, supports the patient and
family in coping with the emotional pain associated
with the disease, improves the stability of their existen-
tial and social life, and ultimately improves adherence
to treatment.
In conclusion, the paradigm of therapeutic education is
the basic element of the AD Intervention Model (Fig. 1).
It considers the relationship with the patient-family the
Fig. 1 Patient educational program for cases of moderate to severe AD
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clinical team works as a whole. When a team approach is
not feasible, this model can still be used as a theoretical
guide for the specialist, even if in a simplified form.
Summary box
 The complexity of care for AD can be summarized
in the following three levels: 1) bio-pharmacological;
2) educational, pedagogical and instructive; 3) psy-
chological/psychotherapeutical
 Therapeutic education allows us to provide not only
technical information about the disease and
corresponding treatments, but also a customized
treatment plan developed in partnership with the
people involved in the case.
 The Intervention model requires a multidisciplinary
team composed of the specialist physician
(pediatrician, allergist, dermatologist), psychologist/
psychotherapist, and other professionals including
nurses, oriented toward improving not only the
disease but also the quality of life of children and
their families.
Conclusion
The Italian Consensus Conference on clinical manage-
ment of atopic dermatitis in children integrates the basic
principles of the most recent guidelines for the manage-
ment of atopic dermatitis to facilitate a practical ap-
proach to the disease. Levels and models of intervention
are also enriched by the Italian experience to facilitate a
practical approach to the disease. The therapeuticalstrategy, and in particular the selection of therapies and
the application of topical products should be adapted to
the clinical severity and require a tailored strategy to en-
sure good compliance by children and their parents.
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